Market Intelligence, Clinical Progress, and High-Purity Reagents for Espin-Targeted Oncology and Gene Therapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for ESPN drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ESPN Recombinant Protein (Full-Length / Key Domains) High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for actin-binding biochemical screens. |
View ESPN Products |
| Gene Delivery | ESPN Promise-ORF / Lentivirus Full-length human ESPN ORF for stable cell line generation in cancer migration or hair cell rescue models. |
View ESPN Products |
| Benchmark Ab | Anti-ESPN Recombinant Antibody Sequence-verified positive control for Western Blot, IHC, and immunofluorescence assays. |
View ESPN Products |
| Validator | ESPN siRNA Set Target-specific knockdown pool for validating phenotypic reliance in metastatic cancer lines. |
View ESPN Products |
| Related Target A | FSCN1 (Fascin-1) Parallel actin-bundling protein and key oncology counter-screening target for selectivity assays. |
View FSCN1 Products |
| Related Target B | MYO15A (Myosin XVa) Co-localized stereocilia partner; critical for genetic deafness rescue co-expression studies. |
View MYO15A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Actin-bundling off-target profiles | High-purity recombinant ESPN and FSCN1 proteins strictly verified by mass spectrometry for parallel counter-screening. |
| Stable expression in fragile cell lines | Lentiviral vectors optimized for high transduction efficiency in auditory and metastatic cell lines. |
| Lack of Controls | Recombinant positive control benchmark antibodies available with sequence validation. |
| False Positives in phenotypic screens | Sequence-verified siRNA pools included to confirm target-specific actin remodeling knockdown. |
Live ESPN R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic development surrounding ESPN (Espin) is diverging into two distinct frontiers: oncology and regenerative medicine. In cancer research, ESPN’s role as an actin-bundling protein that drives filopodia formation and epithelial-mesenchymal transition (EMT) has positioned it as a high-value target for small molecule inhibitors aimed at stopping solid tumor metastasis. Concurrently, in sensory medicine, ESPN gene replacement therapies are advancing rapidly to address autosomal recessive deafness 36 (DFNB36).
The race for ESPN therapeutics is intensifying, with major players shifting focus from traditional systemic treatments to localized gene therapies and highly selective actin-bundling inhibitors. As first-generation therapies reach the clinic, the next wave of R&D is targeting precise molecular interactions within the actin cytoskeleton to minimize systemic toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (AAV/Lenti) | Academic Medical Centers, Gene Therapy Biotechs | DFNB36 Hereditary Deafness | Expression Validation (Need sequence-verified Lentivirus & Western Blot-validated Abs) |
| Small Molecule Inhibitors | Oncology-focused Biotechs | Metastatic Solid Tumors (Pancreatic, Glioma) | Actin-bundling biochemical assays (Need high-purity recombinant ESPN proteins) |
| RNA Therapeutics (siRNA) | RNAi Specialists | Advanced Epithelial Cancers | In vitro knockdown validation (Need target-specific siRNA sets) |